 CAMBRIDGE, Mass., Nov. 09, 2022 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its FHD-286 program will be highlighted in a poster presentation at the Society for Immunotherapy of Cancers SITC 37th Annual Meeting. The meeting will be held November 812, 2022, at the Boston Convention and Exhibition Center and virtually. 